Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Borsotti

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|December 4, 2009
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazolesKatiuscia Bonezzi, Giulia Taraboletti, Patrizia Borsotti, et al.
The American Journal of Pathology|February 13, 2002
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cellsGiulia Taraboletti, Sandra D'Ascenzo, Patrizia Borsotti, et al.
Cancer Research|April 3, 2003
Vascular-targeting activity of ZD6126, a novel tubulin-binding agentGianluca Micheletti, Maura Poli, Patrizia Borsotti, et al.
Carcinogenesis|December 14, 2018
Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanomaLaura Carminati, Denise Pinessi, Patrizia Borsotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Potential antagonism of tubulin-binding anticancer agents in combination therapiesGiulia Taraboletti, Gianluca Micheletti, Romina Dossi, et al.
Neoplasia (New York, N.Y.)|April 14, 2006
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pHGiulia Taraboletti, Sandra D'Ascenzo, Ilaria Giusti, et al.
Cells|April 17, 2020
CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with ChemotherapyAndrea Resovi, Patrizia Borsotti, Tommaso Ceruti, et al.
Cell Death & Disease|March 21, 2026
TSP-1 interaction with RANK and OPG: implications for bone remodeling and osteolytic bone metastasisLaura Carminati, Fabio Sangalli, Chiara Urbinati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesisElitza Naumova, Paolo Ubezio, Angela Garofalo, et al.
Neoplasia (New York, N.Y.)|September 29, 2012
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapiesKatiuscia Bonezzi, Dorina Belotti, Brian J North, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|December 4, 2009
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazolesKatiuscia Bonezzi, Giulia Taraboletti, Patrizia Borsotti, et al.
The American Journal of Pathology|February 13, 2002
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cellsGiulia Taraboletti, Sandra D'Ascenzo, Patrizia Borsotti, et al.
Cancer Research|April 3, 2003
Vascular-targeting activity of ZD6126, a novel tubulin-binding agentGianluca Micheletti, Maura Poli, Patrizia Borsotti, et al.
Carcinogenesis|December 14, 2018
Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanomaLaura Carminati, Denise Pinessi, Patrizia Borsotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
Potential antagonism of tubulin-binding anticancer agents in combination therapiesGiulia Taraboletti, Gianluca Micheletti, Romina Dossi, et al.
Neoplasia (New York, N.Y.)|April 14, 2006
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pHGiulia Taraboletti, Sandra D'Ascenzo, Ilaria Giusti, et al.
Cells|April 17, 2020
CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with ChemotherapyAndrea Resovi, Patrizia Borsotti, Tommaso Ceruti, et al.
Cell Death & Disease|March 21, 2026
TSP-1 interaction with RANK and OPG: implications for bone remodeling and osteolytic bone metastasisLaura Carminati, Fabio Sangalli, Chiara Urbinati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesisElitza Naumova, Paolo Ubezio, Angela Garofalo, et al.
Neoplasia (New York, N.Y.)|September 29, 2012
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapiesKatiuscia Bonezzi, Dorina Belotti, Brian J North, et al.
Pageof 3